BLZ-945丨CAS 953769-46-5

BLZ-945 (CAS 953769-46-5) is a highly selective inhibitor of the colony-stimulating factor 1 receptor (CSF-1R), a key regulator of monocyte, macrophage, and osteoclast function. It is primarily used in pharmaceutical research and drug development, particularly in oncology and neuroinflammatory disease studies. In cancer research, BLZ-945 is employed to modulate the tumor microenvironment by depleting tumor-associated macrophages (TAMs) and promoting the infiltration of cytotoxic CD8+ T cells, which enhances antitumor immune responses. Additionally, it is applied in neurological research for investigating microglial activity and promoting remyelination in demyelinating disease models. Its selectivity and potency make it a valuable tool for preclinical and clinical studies aimed at understanding and manipulating CSF-1R signaling in disease contexts.

The benefits of BLZ-945 arise from its high potency, selectivity, and ability to precisely modulate immune and inflammatory pathways. By targeting CSF-1R, it effectively reduces the number and activity of tumor-supporting macrophages without broadly suppressing other immune cells, which can improve therapeutic outcomes and reduce off-target effects. In cancer research, this selective modulation helps enhance the effectiveness of immunotherapies and slows tumor progression. In neuroinflammatory studies, BLZ-945 promotes beneficial microglial activity, supporting tissue repair and remyelination. Its well-defined pharmacological profile also enables precise dose optimization and controlled mechanistic studies, making it a reliable candidate for drug development and translational research.